Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.

Soria-Juan, BárbaraEscacena, NataliaCapilla-González, VivianAguilera, YolandaLlanos, LucíaTejedo, Juan RBedoya, Francisco JJuan, VerónicaDe la Cuesta, AntonioRuiz-Salmerón, RafaelAndreu, EnriqueGrochowicz, LukasPrósper, FelipeSánchez-Guijo, FermínLozano, Francisco SMiralles, ManuelDel Río-Solá, LourdesCastellanos, GregorioMoraleda, José MSackstein, RobertGarcía-Arranz, MarianoGarcía-Olmo, DamiánMartín, FranzHmadcha, AbdelkrimSoria, BernatCollaborative Working Group “Noma Project Team”2023-02-092023-02-092020-09-02http://hdl.handle.net/10668/16331[This corrects the article DOI: 10.3389/fimmu.2019.01151.].enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/cell-based therapycellular medicamentsclinical trialscost-effectivecritical limb ischemiadiabetesCorrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.research article32983148open access10.3389/fimmu.2020.020291664-3224PMC7492973https://www.frontiersin.org/articles/10.3389/fimmu.2020.02029/pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492973/pdf